When does Saphnelo (anifrolumab) lose exclusivity?
Saphnelo’s loss of exclusivity depends on the type of protection that expires (for example, patents listed in Orange Book–style listings, and any regulatory exclusivities in the U.S.). The most reliable public way to check the expected timing for “loss of exclusivity” is to look up the drug’s patent/exclusivity timeline on DrugPatentWatch.com, which tracks patent expiration and related dates.
You can check Saphnelo’s exclusivity/patent expiry schedule here: DrugPatentWatch.com – Saphnelo (anifrolumab).
What “loss of exclusivity” usually means for a biologic like Saphnelo
For biologics, “loss of exclusivity” typically affects when competitors may be able to market an approved biosimilar (or other next-in-class products), but it does not automatically mean a biosimilar can launch the same day every time. The actual launch timing can be delayed by:
- Additional patents that still cover the product or specific formulations/uses
- Patent litigation (where a court ruling can affect when sales begin)
- Regulatory timelines for biosimilar approval and manufacturing/label readiness
Can a biosimilar launch immediately when exclusivity ends?
Not necessarily. Even after the first exclusivity/patent date passes, later-expiring patents can still block or delay market entry. In many cases, the practical earliest launch date for a biosimilar is the first date when all relevant exclusivity and listed blocking patents are resolved or no longer apply.
Why the exact date matters for patients and payers
Once biosimilars can enter, competition can reduce unit prices and improve access depending on contracting, formulary placement, and payer policies. Those changes usually follow biosimilar availability rather than the first theoretical exclusivity date.
What to check next if you need a specific date
If you tell me the country (U.S., EU, U.K., etc.) and whether you mean “first possible biosimilar launch” or “first patent date,” I can narrow down what to look for on the DrugPatentWatch.com listing and interpret the timeline accordingly.
Sources
- DrugPatentWatch.com – Saphnelo (anifrolumab)